One million meningitis eases occur every year over the world: the inci
dence rate reaches 20/100000. Developing countries have the highest in
cidence and mortality rate; average mortality is 20%:less than 10% in
developed countries; it can reach over 50% in some places, Sequela, es
pecially deafness, are estimated at over 5%. In endemic regions H. inf
luenzae (20 to 40% of the isolates) is one of the most common agent in
children under 5 years of age, pneumococcus (15 to 30%) affects infan
ts and elderly people; meningococcus is widespread, especially among y
oung adults. Incidence varies a lot according to preexisting condition
s, ethnic and social characteristics, seasons and regions. Meningococc
us A and C strains are responsible for large epidemics in tropical cou
ntries and some outbreaks in mild climate countries. Third generation
cephalosporins are now being used because an increasing number of H. i
nfluenzae strains are resistant to ampicillin. The high prevalence of
beta-lactamin resistant pneumococcus is quite preoccupying. Hib vaccin
ation in some developed countries is very promising and modifies the e
pidemiology of meningitis in children. Meningitis prevention is a good
reason to develop vaccination programs. Improving data collection on
meningitis and determining groups at risk would be useful for preventi
on policies.